Multiple Myeloma

The FDA approved iberdomide plus daratumumab and dexamethasone for relapsed/refractory multiple myeloma.

Adam D. Cohen, MD, discusses the mechanism of action of cevostamab in relapsed/refractory multiple myeloma.

Rafael Fonseca, MD, discusses how FISH, NGS, and minimal residual disease testing guide risk stratification and treatment in multiple myeloma.

In case you missed any, read a recap of the episodes of OncLive On Air that aired in July 2026.

The top 5 OncLive TV videos of the week cover insights in melanoma, prostate cancer, breast cancer, multiple myeloma, and small cell lung cancer.

Adam D. Cohen, MD, discusses future research directions for cevostamab in relapsed/refractory multiple myeloma.

Adam D. Cohen, MD, discusses phase 1 efficacy data for cevostamab in relapsed/refractory multiple myeloma.

Adam D. Cohen, MD, overviews phase 1 findings for cevostamab and outlines future research directions for the agent in relapsed/refractory multiple myeloma.

Adam D. Cohen, MD, discusses the potential role of FcRH5 as a target and the ongoing investigation of cevostamab in multiple myeloma.

Douglas W. Sborov, MD, MS, discussed the FDA approval of isatuximab for subcutaneous injection in multiple myeloma indications.

The FDA accepted an NDA for daraxonrasib in metastatic pancreatic cancer, approved zidesamtinib in pretreated ROS1-positive NSCLC, and more.

Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.

Teclistamab plus talquetamab met the primary PFS end point and improved overall survival in relapsed/refractory multiple myeloma in MonumenTAL-6.

The top 5 OncLive TV videos of the week cover insights in bladder cancer, chronic myeloid leukemia, multiple myeloma, pancreatic cancer, and chronic lymphocytic leukemia.

The FDA approved gedatolisib in PIK3CA wild-type breast cancer, granted full approval to selpercatinib in RET fusion+ tumors, and more.

Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.

Experts shared the key data that stood out in hematologic oncology at the 2026 ASCO Annual Meeting.

Claudio Cerchione, MD, PhD, discusses the significance of the FDA approval of subcutaneous isatuximab in multiple myeloma.

An OncLive Scientific Interchange and Workshop covered sequencing, toxicity management, and access barriers for CAR T-cell therapy in multiple myeloma.

Readouts across LBCL, relapsed/refractory myeloma, and CALR-mutated myelofibrosis anchored the hematology data presented at EHA 2026.

The FDA accepted a new drug application for mezigdomide plus carfilzomib and dexamethasone for relapsed/refractory multiple myeloma.

In case you missed any, check out our recap of the episodes of OncLive On Air that aired in June 2026.

Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.

The FDA approved subcutaneous isatuximab delivered via an on-body injector for multiple myeloma.

Hematologic oncology experts outline the top data and themes to emerge from the 2026 EHA Congress